67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details

臨床試験数 : 216 / 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151

9 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04680780 (ClinicalTrials.gov)	January 10, 2021	1/10/2020	Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	ADPKD	Other: Ketogenic diet;Other: 3-days water-fasting;Other: Control	University of Cologne	NULL	Active, not recruiting	18 Years	60 Years	All	63	N/A	Germany
2	NCT03102632 (ClinicalTrials.gov)	June 1, 2017	27/3/2017	A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease	A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease	Autosomal Dominant Polycystic Kidney	Other: High Water Intake	The Rogosin Institute	Weill Medical College of Cornell University	Active, not recruiting	18 Years	65 Years	All	10	N/A	United States
3	NCT02933268 (ClinicalTrials.gov)	September 26, 2016	18/9/2016	High Water Intake in Polycystic Kidney Disease	Determining Feasibility of Randomisation to High vs ad Libitum Water Intake in Polycystic Kidney Disease: The DRINK Randomised Feasibility Trial	Autosomal Dominant Polycystic Kidney Disease	Dietary Supplement: High water intake;Other: Ad libitum water intake	Cambridge University Hospitals NHS Foundation Trust	PKD Charity;Addenbrookes Charitable Trust;British Renal Society & British Kidney Patient Association	Completed	16 Years	N/A	All	42	N/A	United Kingdom
4	NCT02776241 (ClinicalTrials.gov)	September 2015	4/5/2016	Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease	Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney: The HYDRA Study	ADPKD	Other: water	Rigshospitalet, Denmark	Aarhus University Hospital	Completed	18 Years	N/A	All	40	N/A	Denmark
5	NCT02527863 (ClinicalTrials.gov)	February 2015	18/2/2015	Effect of the Aquaretic Tolvaptan on Nitric Oxide System	The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Central Hemodynamics During Baseline Conditions and After Inhibition of the Nitric Oxide System in Patients With Autosomal Dominant Polycystic Kidney Disease	Autosomal Dominant Polycystic Kidney Disease	Drug: Tolvaptan;Drug: Placebo	Regional Hospital Holstebro	Aarhus University Hospital	Completed	18 Years	65 Years	All	18	Phase 2	Denmark
6	EUCTR2014-001973-15-DK (EUCTR)	18/11/2014	27/06/2014	The effcts of tolvaptan on renal handling of water and salt, hormones in the blood at the circulation, during blocking of the nitric oxide (NO) system in patients with autosomal dominant polycystic kidney disease	Renal Handling of Water and Sodium in Autosomal Dominant Polycystic Kidney Disease.The effects of tolvaptan on renal handling of water and sodium , vasoactive hormones and central hemodynamics during baseline conditions and after inhibition of the nitric oxide system in patients with autosomal dominant polycystic kidney disease - TOPO	HyponatreamiaSIADH ( Syndrome of Inappropriate Antidiuretic Hormone Secretion) OverhydrationAutosomal dominant polycystic kidney disease MedDRA version: 17.0;Level: LLT;Classification code 10021038;Term: Hyponatremia;System Organ Class: 100000004861 MedDRA version: 17.0;Classification code 10040626;Term: SIADH;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07]	Trade Name: Samsca Product Name: Tolvaptan Product Code: C03XA01 INN or Proposed INN: Tolvaptan Other descriptive name: TOLVAPTAN	University Clinic in Nephrology and Hypertension, Department of Medical Research	NULL	Not Recruiting			Female: yes Male: yes			Denmark
7	NCT02225860 (ClinicalTrials.gov)	May 2014	20/8/2014	Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease	Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKD	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Behavioral: Diet and water adjustment	Tufts Medical Center	NULL	Completed	18 Years	60 Years	All	34	Phase 2/Phase 3	United States
8	NCT00784030 (ClinicalTrials.gov)	November 2008	31/10/2008	High Water Intake to Slow Progression of Polycystic Kidney Disease	The Effect of Water Loading on Urinary Biomarkers	Kidney, Polycystic, Autosomal Dominant	Other: Water	New York University School of Medicine	NULL	Completed	18 Years	65 Years	All	23	N/A	United States
9	NCT00759369 (ClinicalTrials.gov)	September 2008	24/9/2008	Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Water as Therapy in Autosomal Dominant Polycystic Kidney Disease	Autosomal Dominant Polycystic Kidney Disease	Other: Water prescription	University of Kansas	NULL	Completed	18 Years	50 Years	Both	11	N/A	United States

先頭へ